Recommendations for the prevention and treatment of influenza using antiviral drugs based on cost-effectiveness.
Identifieur interne : 001866 ( PubMed/Curation ); précédent : 001865; suivant : 001867Recommendations for the prevention and treatment of influenza using antiviral drugs based on cost-effectiveness.
Auteurs : Pedro Plans [Espagne]Source :
- Expert review of pharmacoeconomics & outcomes research [ 1744-8379 ] ; 2008.
Abstract
Influenza is an acute respiratory disease that causes epidemics and pandemics in the human population of temperate regions. Influenza epidemics occur every year during the winter months, affecting approximately 10% of the population. The primary strategy for reducing the effect of influenza in the community is to vaccinate persons who are at risk or caring for high-risk individuals each year before seasonal increases in influenza virus circulation occur. Antiviral drugs can be used for the treatment of influenza and the prevention of seasonal and post-exposure influenza. Four antiviral drugs are available for the prevention and treatment of influenza infections: oseltamivir, zanamivir, rimantadine and amantadine. Antiviral drugs can be used for the treatment of influenza and for post-exposure and seasonal influenza prevention. The cost-effectiveness of antiviral therapies ranged from cost savings to more than US$130,000 per quality-adjusted life-year (QALY) for influenza treatment, from GB pound9000 to more than pound1 million per QALY for seasonal prevention and from cost savings to pound100,000 per QALY for post-exposure prevention. Based on the cost-effectiveness threshold of pound30,000 or $40,000 per QALY, antiviral therapies can be recommended for influenza treatment and post-exposure prevention in healthy and high-risk individuals and for seasonal prevention in high-risk individuals. Zanamivir, oseltamivir and amantadine have favorable cost-effectiveness ratios for these interventions, but amantadine should only be used in countries with a low prevalence of resistant virus. The stockpile of antiviral drugs should be maintained in developed countries because they are cost effective for the prevention and treatment of a possible influenza pandemic.
DOI: 10.1586/14737167.8.6.563
PubMed: 20528367
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001866
Links to Exploration step
pubmed:20528367Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recommendations for the prevention and treatment of influenza using antiviral drugs based on cost-effectiveness.</title><author><name sortKey="Plans, Pedro" sort="Plans, Pedro" uniqKey="Plans P" first="Pedro" last="Plans">Pedro Plans</name><affiliation wicri:level="1"><nlm:affiliation>Direcció General de Salut Pública, Departament de Salut, Generalitat de Catalunya, Roc Boronat 83-95, Barcelona 08005, Spain. pedro.plans@gencat.cat.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Direcció General de Salut Pública, Departament de Salut, Generalitat de Catalunya, Roc Boronat 83-95, Barcelona 08005</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:20528367</idno><idno type="pmid">20528367</idno><idno type="doi">10.1586/14737167.8.6.563</idno><idno type="wicri:Area/PubMed/Corpus">001866</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001866</idno><idno type="wicri:Area/PubMed/Curation">001866</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001866</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Recommendations for the prevention and treatment of influenza using antiviral drugs based on cost-effectiveness.</title><author><name sortKey="Plans, Pedro" sort="Plans, Pedro" uniqKey="Plans P" first="Pedro" last="Plans">Pedro Plans</name><affiliation wicri:level="1"><nlm:affiliation>Direcció General de Salut Pública, Departament de Salut, Generalitat de Catalunya, Roc Boronat 83-95, Barcelona 08005, Spain. pedro.plans@gencat.cat.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Direcció General de Salut Pública, Departament de Salut, Generalitat de Catalunya, Roc Boronat 83-95, Barcelona 08005</wicri:regionArea></affiliation></author></analytic><series><title level="j">Expert review of pharmacoeconomics & outcomes research</title><idno type="eISSN">1744-8379</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza is an acute respiratory disease that causes epidemics and pandemics in the human population of temperate regions. Influenza epidemics occur every year during the winter months, affecting approximately 10% of the population. The primary strategy for reducing the effect of influenza in the community is to vaccinate persons who are at risk or caring for high-risk individuals each year before seasonal increases in influenza virus circulation occur. Antiviral drugs can be used for the treatment of influenza and the prevention of seasonal and post-exposure influenza. Four antiviral drugs are available for the prevention and treatment of influenza infections: oseltamivir, zanamivir, rimantadine and amantadine. Antiviral drugs can be used for the treatment of influenza and for post-exposure and seasonal influenza prevention. The cost-effectiveness of antiviral therapies ranged from cost savings to more than US$130,000 per quality-adjusted life-year (QALY) for influenza treatment, from GB pound9000 to more than pound1 million per QALY for seasonal prevention and from cost savings to pound100,000 per QALY for post-exposure prevention. Based on the cost-effectiveness threshold of pound30,000 or $40,000 per QALY, antiviral therapies can be recommended for influenza treatment and post-exposure prevention in healthy and high-risk individuals and for seasonal prevention in high-risk individuals. Zanamivir, oseltamivir and amantadine have favorable cost-effectiveness ratios for these interventions, but amantadine should only be used in countries with a low prevalence of resistant virus. The stockpile of antiviral drugs should be maintained in developed countries because they are cost effective for the prevention and treatment of a possible influenza pandemic.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">20528367</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2010</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-8379</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Expert review of pharmacoeconomics & outcomes research</Title><ISOAbbreviation>Expert Rev Pharmacoecon Outcomes Res</ISOAbbreviation></Journal><ArticleTitle>Recommendations for the prevention and treatment of influenza using antiviral drugs based on cost-effectiveness.</ArticleTitle><Pagination><MedlinePgn>563-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1586/14737167.8.6.563</ELocationID><Abstract><AbstractText>Influenza is an acute respiratory disease that causes epidemics and pandemics in the human population of temperate regions. Influenza epidemics occur every year during the winter months, affecting approximately 10% of the population. The primary strategy for reducing the effect of influenza in the community is to vaccinate persons who are at risk or caring for high-risk individuals each year before seasonal increases in influenza virus circulation occur. Antiviral drugs can be used for the treatment of influenza and the prevention of seasonal and post-exposure influenza. Four antiviral drugs are available for the prevention and treatment of influenza infections: oseltamivir, zanamivir, rimantadine and amantadine. Antiviral drugs can be used for the treatment of influenza and for post-exposure and seasonal influenza prevention. The cost-effectiveness of antiviral therapies ranged from cost savings to more than US$130,000 per quality-adjusted life-year (QALY) for influenza treatment, from GB pound9000 to more than pound1 million per QALY for seasonal prevention and from cost savings to pound100,000 per QALY for post-exposure prevention. Based on the cost-effectiveness threshold of pound30,000 or $40,000 per QALY, antiviral therapies can be recommended for influenza treatment and post-exposure prevention in healthy and high-risk individuals and for seasonal prevention in high-risk individuals. Zanamivir, oseltamivir and amantadine have favorable cost-effectiveness ratios for these interventions, but amantadine should only be used in countries with a low prevalence of resistant virus. The stockpile of antiviral drugs should be maintained in developed countries because they are cost effective for the prevention and treatment of a possible influenza pandemic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Plans</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Direcció General de Salut Pública, Departament de Salut, Generalitat de Catalunya, Roc Boronat 83-95, Barcelona 08005, Spain. pedro.plans@gencat.cat.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Pharmacoecon Outcomes Res</MedlineTA><NlmUniqueID>101132257</NlmUniqueID><ISSNLinking>1473-7167</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20528367</ArticleId><ArticleId IdType="doi">10.1586/14737167.8.6.563</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001866 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001866 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:20528367
|texte= Recommendations for the prevention and treatment of influenza using antiviral drugs based on cost-effectiveness.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:20528367" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |